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ABSTRACT According to the “desmoglein compensation theory,” anti-Dsg1 and anti-Dsg3 
profiles are crucial for the clinical outcome of pemphigus vulgaris. However, recent studies 
have highlighted several cases with an incompatibility between the antibody profile and 
clinical manifestation. Data of 37 patients who had been diagnosed pemphigus vulgaris in 
our Department between January 2014-June 2016 were retrieved from our clinical data-
base. Patients with ABSIS skin involvement scores, oral mucosa extent and severity scores, 
anti-Dsg1 and Dsg3 antibody profile were included in this retrospective study. Patients with 
discordance between clinical manifestations and immunological profile were considered as 
atypical clinical phenotype. Patients with missing data were excluded. In all 37 patients, Dsg1 
and Dsg3 antibody titers at the baseline did not correlate with the concurrent ABSIS scores. 
At follow up, we detected statistically significant correlations between anti Dsg-1 profile and 
ABSIS skin involvement scores (p=0.006; r=0.588) and between anti-Dsg3 and ABSIS mucosal 
extent and severity scores (p=0.058; r=0.431). After treatment, the reduction of Dsg-1 anti-
body titers was statistically significant in remittent patients (p=0.027). We did not detect sta-
tistically significant reduction of Dsg-3 antibodies. Four subjects had incompatible antibody 
profile and clinical activity.  Discordance between phenotype-antibody profile and clinical 
activity-Dsg titers support the idea that non-Dsg antigens may also be the target for pemphi-
gus autoimmunity.
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INTRoduCTIoN
Pemphigus is a group of cutaneous autoimmune 
blistering diseases caused by IgG autoantibodies, 
which mainly target two desmosomal proteins, des-
moglein 1 (Dsg1), and desmoglein 3 (Dsg3). Localiza-
tion of the blister formation are explained by “desmo-
glein compensation theory”. It is well-accepted that 
anti-Dsg1 and anti-Dsg3 profiles are crucial for the 
clinical outcome of the disease. However, recent stud-
ies have highlighted several cases with an incompat-
ibility between the antibody profile and clinical man-
ifestation (1-8). In addition, there is conflicting data 
about the utility of screening antibody titers during 
the follow-up period. In the literature, patients who 
are in remission yet still having positive anti-Dsg3 lev-
els have been reported (2, 4, 9, 10). 
The Autoimmune Bullous Skin Disorder Intensity 
Score (ABSIS) is a validated scoring system to measure 
and capture changes in the disease activity (11). Since 
ABSIS is a reliable tool for evaluating the clinical activity 
of the disease, it has also been used in studies addressing 
the correlation between antibody profiles and clinical 
activity (9, 11). With respect to determining qualitative 
changes of mucosal disease in cases without any lesion 
size or number change, the combination of objective 
and subjective components may result in a comprehen-
sive validation for oral mucosa involvement (11).
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In this report, we aimed to improve our under-
standing of the link between clinical and immunolog-
ical responses. We present the results of data analysis 
from 37 patients with the diagnosis of pemphigus 
vulgaris (PV) and describe a unique subset of patients 
with discordance between their antibody profile and 
clinical picture.
PATIENT ANd METhodS
From the database of our Dermatology clinic we 
collected the data on 74 patients with the ICD code 
of pemphigus vulgaris in the period between Janu-
ary 2014 and June 2016. The patients who had a 
diagnosis other than PV, including pemphigus folia-
ceus, paraneoplastic pemphigus or other bullous dis-
orders, during their follow-up and patients with the 
lack of clinical or immunological data were excluded. 
Thirty-seven patients were included in the final analy-
sis. They were diagnosed according usual clinical, his-
topathological and immunological criteria. The clini-
cal diagnosis was made on the basis of the existence 
of the depositions of IgG with or without C3 on the 
epithelial cell surface on direct immunofluorescence, 
flaccid blisters and/or erosions observed in the mu-
cosa, skin, or both and intraepidermal blisters with 
acantholysis in histopathological examination (12).
We recorded the following data from the medical 
charts: age, gender, ABSIS skin and mucosa scores. AB-
SIS skin involvement scores, oral mucosa extent and 
severity scores were recorded separately. The titers of 
circulating antibodies were measured using the con-
ventional enzyme-linked immunoassay (ELISA) kit. 
Anti-Dsg 1 and anti-Dsg3 profiles were measured at 
two time-points (baseline with/without follow-up) in 
18 patients and only during the follow-up period in 
19 patients. We compared these immunological pro-
files and concurrent ABSIS scores of the patients. The 
cases with antibody profiles that did not conform to 
compensation theory were discussed based on simi-
lar case reports, author’s opinions and experimental 
studies. Also patients with immunological reactivity 
despite the sucessful control of the disease activity 
were also included in the study.
STATISTICAL ANALySIS
Statistical analyses were performed using IBM 
SPSS for Windows Version 21.0 package program 
(IBM, USA). Numerical variables were tested for nor-
mality using visual (histogram, normality plots) and 
analytic (Kolmogorov-Smirnov test, variation coeffi-
cient and Kurtosis/Skewness index) tests. Categorical 
variables were presented as numbers and percentag-
es and numerical variables were presented as mean ± 
standard deviation or median and interquartile range 
(IQR). Categorical variables were compared using chi-
square test or Fisher’s exact test; Mann Whitney U test 
was used for paired group comparison of numerical 
variables in case condition of normal distribution was 
not met. Correlation analysis was performed using 
Spearman’s correlation test. The level of statistical 
significance was set at p<0.05. 
RESuLTS
Twenty-three female and 14 male patients were 
included to the study. The mean age was 50 years 
(ranging 27-74). The median mucosal involvement 
extent and severity scores were 2.19 and 18.6, respec-
tively. The mean skin involvement score was 20.72 at 
initial presentation. Oral mucosa ABSIS scores were 
similar in both genders but skin ABSIS scores were 
higher in female than male patients (p=0.046) At 
baseline, Dsg1 and Dsg3 titers did not correlate with 
the ABSIS oral mucosa severity scores. We detected 
statistically significant correlations at follow-up be-
tween anti Dsg-1 profile and ABSIS skin involvement 
scores (p=0.006; r=0.588) and between anti-Dsg3 and 
ABSIS mucosal extent and severity scores (p=0.058; 
r=0.431). After the treatment period in remittent 
patients, the reduction of Dsg-1 antibody titers was 
statistically significant (p=0.027). On the other hand, 
we did not detect statistically significant reduction of 
Dsg-3 antibodies in the post-treatment period.
We observed one case of cutaneous pemphigus 
without Dsg1 positivity, one mucosal pemphigus 
without Dsg-1 and Dsg-3 positivity and two cutane-
ous pemphigus with Dsg3 positivity (Table 1). These 
patients were considered to have an atypical clini-
cal phenotype. Anti-Dsg3 titers of five patients with 
successfully controlled of disease activity remained 
at higher levels during the follow-up period (Table 
2). The average length of time to achieving the con-
trol of disease activity in these five patients was 10.4 
months (range 6-12 months).
dISCuSSIoN
The compensation theory suggests that antibod-
ies against Dsg1 and/or 3 are adequate to disrupt epi-
dermal integrity (13). However, in recent years it has 
been proposed that the compensation theory based 
on this monopathogenetic justification is insufficient 
to explain pemphigus pathogenesis (14, 15). 
Studies regarding the correlation between ELISA 
testing for anti-Dsg1 and anti-Dsg3 with disease ac-
tivity and clinical phenotype have conflicting results. 
Some studies report that serum testing for antibod-
ies against desmoglein 1 and 3 correlates well with 
the severity of disease (8) and is a good tool for moni-
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toring disease activity (5-7). Contrary to these results, 
some authors think desmoglein ELISA testing is not 
practical for the follow-up (4). In addition, anti-Dsg1 
reactivity is found more predictive for disease activity 
(2, 3). In our study, significant reduction of the Dsg 
3 autoantibodies was not observed in patients with 
remission. In the light of the scientific literature this 
may be explained by the presence of non-Ca+2 depen-
dent epitopes or predominance of non-pathogenic 
IgG1 versus IgG4 (16-18).
The monopathogenetic hypothesis cannot ex-
plain the observed negativity of both anti-Dsg1 and 
anti-Dsg3 antibodies seen in 5-33% of patients with 
pemphigus vulgaris (1, 19-24). Similarly, in our series, 
one of our cases (5.5%) had negative ELISA results 
for both anti-Dsg1 and anti-Dsg3. There are reports 
in literature on patients with anti-Dsg3 positivity in 
the absence of oral mucosal involvement (25-27), 
patients with oral mucosal involvement despite anti-
Dsg3 negativity (28, 29), cutaneous pemphigus vul-
garis cases lacking Dsg1 autoantibodies (30) and the 
discordance between clinical activity and Dsg titers 
(2, 4).
According to the multipathogenetic explanation, 
as opposed to the monopathogenetic hypothesis, 
other coexisting pathogenic antibodies rather than 
a monotypic pathogenic antibody lead to the simul-
taneous influence of multiple biological functions of 
keratinocytes, and the activity of anti-Dsg antibodies 
is augmented by non-Dsg antibodies (14). In a study 
which investigated the complementary activities of 
non-Dsg and anti-Dsg antibodies, it was established 
that acantholysis due to anti-mitochondrial antibodies 
(AMA) is reversible, contrary to the irreversible acanthol-
ysis effect of AMA coupled with anti-Dsg antibodies (31). 
It was demonstrated that high doses of monoclonal 
anti-Dsg antibodies can lead to acantholysis, but this 
effect was absent at low antibody dilutions (31). Inter-
estingly, acantholysis occurred when AMA was added 
to a non-acantholytic concentration of anti-Dsg anti-
bodies (31). According to these findings, either anti-
Dsg or non-Dsg autoantibodies are believed to be 
responsible for the development of the acantholysis 
in pemphigus (14). In relation to this finding, Sajda 
et al. reported non-desmoglein reactivities toward 
muscarinic acetylcholine receptor subtypes 3,4,5 and 
thyroid peroxidase in PV patients (32).
In the report of Grando et al. (15), the existence 
of over 50 proteins that interact with the pemphigus 
IgG type antibody, generation of desmosomes by 
Dsg1-3 deficient keratinocytes due to gene silencing 
(33), and suprabasal acantholysis observed in Dsg3 
neonates after the transfer of antibodies from pa-
tients with pemphigus vulgaris (34), provide support-
ing evidence for the inadequacy of the compensation 
theory.
Lower pathogenicity of anti-Dsg3 antibodies is 
another explanation for atypical clinical presenta-
tion (35). According to this hypotheses, low levels 
of pathogenic antibodies are sufficient to block skin 
Dsg3 accompanied by anti-Dsg1 antibodies, but not 
of the oral mucosal Dsg3, where Dsg3 is dominant 
(25). Although it is not possible to make strong con-
clusions based on the retrospective design of our 
study and lack of long-term follow-up, we believe 
that our findings and other relevant data call for fur-
ther review of compensation theory and monopatho-
genic hypothesis. 
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69 M NEGATIVE 1:1000 5 39 35
66 M 1:100 1:320 5 39 10
59 F NEGATIVE 1:1000 0 0  18*
53 F NEGATIVE 1:320 3 30 45
52 F NEGATIVE 1:1000 5 42 15
45 M NEGATIVE 1:1000 3 30 45
35 M 1:200 1:200 4 30 45
36 M NEGATIVE 1:320 3 30 45
51 F NEGATIVE NEGATIVE 4 30 0*
33 F NEGATIVE 1:320 3 30 0
55 M NEGATIVE 1:320 6 42 0
73 F 1:320 1:1000 3 30 45
55 F NEGATIVE 1:100 5 39 0
27 M 1:320 1:320 0 0 50*
69 F NEGATIVE 1:320 5 39 0
56 F 1:320 1:1000 6 42 60
43 F 1:200 1:320 0 0 60*
50 M 1:100  1:1000  10 42 5
* Patients with an incompatibility between the antibody profile and clinical manifestation at initial presentation
Table 1. Baseline Dsg antibody levels of 18 of patients
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CoNCLuSIoN
The discordance between phenotype-antibody 
profile and between clinical activity-Dsg titers sup-
ports the idea of non-Dsg antigens having a key role in 
pemphigus autoimmunity.
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duratin of CR 
(months) 
Treatment  at the time 





48/F 10 16 mg/day Pred., 50 mg/day AZA NEGATIVE 1/1000
34/F 12 7,5/day Metilpred., 100mg/day AZA NEGATIVE NEGATIVE
38/F 12 100 mg/day AZA, IVIg NEGATIVE 1/320
70/M 12  5 mg/day Fluocort. 50 mg/day AZA NEGATIVE 1/200
54/M 12 100 mg/day AZA NEGATIVE 1/320
42/M 9  IVIg NEGATIVE NEGATIVE
53/M 12 5 mg/day metilpred., 50 mg/day AZA NEGATIVE NEGATIVE
53/M 6 32 mg/day pred., 100 mg/day AZA NEGATIVE 1/320
Pred.: prednisolone, Metilpred.: methylprednisolone, AZA: azathioprine, Fluocort.: fluocortolone
Table 2. Dsg 1 and Dsg 3 titers of patients in clinical remission (CR)
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